Endo International announced that its Par Sterile Products business has begun shipping premixed Ephedrine Sulfate Injection in a ready-to-use 50 mg/10 ml single-use vial.
"We are pleased to launch this new ready-to-use product as part of our agreement with Nevakar," said Scott Sims, Senior Vice President and General Manager, Sterile Products at Endo. "This is a demonstration of our commitment to deliver quality, life-enhancing therapies to healthcare providers—when and how they need them."
Ready-to-use, or RTU, products help streamline operations for hospitals by eliminating the need to prepare or transfer the product before patient administration. This may reduce waste and costs, optimize convenience and workflow, and heighten accuracy and compliance by reducing the chance for preparation error—all of which support quality patient care.
This is the first product launch under the previously announced exclusive licensing agreement between Nevakar Injectables, Inc., a privately held biopharmaceutical company, and Endo's subsidiary, Endo Ventures Limited (EVL). Under the agreement, the companies are collaborating on five differentiated sterile injectable products in the U.S. Nevakar is responsible for developing the drugs and obtaining approval from the U.S. Food and Drug Administration, and EVL is responsible for product launch and distribution through Endo's Par Sterile Products business.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!